Svoz Adverse Reactions

Svoz: Undesirable Effects are found during treatment with Moxifloxacin as shown in the table as follows: See table.

Click on icon to see table/diagram/image

Svoz Infusion: Undesirable Effects may be found during treatment with Moxifloxacin as shown in the following: Cardiovascular disorders: angina pectoris, atrial fibrillation, bradycardia, cardiac arrest, cardiac failure, chest discomfort, chest pain, edema, hypertension, hypotension, increase blood pressure, palpitation, peripheral edema, phlebitis, prolonged Q-T interval on ECG, syncope, tachycardia.
Central nervous system disorders: agitation, anxiety, chills, confusion, depression, disorientation, dizziness, drowsiness, facial pain, fatigue, hallucination, headache, hypoesthesia, insomnia, lethargy, malaise, nervousness, noncardiac chest pain, pain, paresthesia, restlessness, vertigo.
Dermatologic disorders: allergic dermatitis, erythema, hyperhidrosis, night sweats, pruritus, skin rash, urticaria.
Endocrine & metabolic system disorders: decreased serum glucose, dehydration, hyperchloremia, hyperglycemia, hyperlipidemia, hypokalemia, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum albumin, increased serum glucose, increased serum triglycerides, increased uric acid.
Gastrointestinal disorders: abdominal discomfort, abdominal distension, abdominal pain, anorexia, constipation, decreased amylase, decreased appetite, diarrhea, dysgeusia, flatulence, gastritis, gastroenteritis, gastroesophageal reflux disease, increased amylase, increased serum lipase, nausea, oral candidiasis, vomiting, xerostomia.
Genitourinary disorders: dysuria, fungal vaginosis, vaginal infection, vulvovaginal candidiasis, vulvovaginal pruritus.
Hematologic disorders: anemia, decreased basophils, decreased hematocrit, decreased hemoglobin, decreased neutrophils, decreased prothrombin time, decreased red blood cells, eosinopenia, eosinophilia, increased MCH, increased neutrophils, leukocytosis, leukopenia, prolonged partial thromboplastin time, prolonged prothrombin time, thrombocythemia, thrombocytopenia.
Hepatic disorders: abnormal hepatic function tests, decreased serum bilirubin, increased liver enzymes, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum transaminases.
Hypersensitivity: hypersensitivity reaction.
Immunologic disorders: increased serum globulins.
Infection: candidiasis, fungal infection (including oral).
Local: extravasation.
Neuromuscular & skeletal disorders: arthralgia, back pain, limb pain, muscle spasms, musculoskeletal pain, myalgia, tremor, weakness.
Ophthalmic disorder: blurred vision.
Otic disorder: tinnitus.
Renal disorders: increased blood urea nitrogen, increased ionized serum calcium, increased serum creatinine, renal failure.
Respiratory disorders: asthma, bronchospasm, dyspnea, hypoxia, wheezing.
Miscellaneous: fever.
Rare but important or life-threatening: agranulocytosis, anaphylactic shock, anaphylactoid reaction, anaphylaxis, aplastic anemia, ataxia, auditory impairment, cholestatic jaundice, Clostridium difficile associated diarrhea, deafness (reversible), decreased INR, ECG abnormality, exacerbation of myasthenia gravis, hemolytic anemia, hepatic failure, hepatic necrosis, hepatitis (predominantly cholestatic), hepatotoxicity (idiosyncratic), hypoglycemia, increased intracranial pressure, interstitial nephritis, jaundice, pancytopenia, peripheral neuropathy (may be irreversible), phototoxicity, pneumonitis (allergic), polyneuropathy, pseudomembranous colitis, pseudotumor cerebri, psychotic reaction, renal insufficiency, rupture of tendon, seizure, skin photosensitivity, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, tendonitis, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis, ventricular tachyarrhythmias (including torsades de pointes and cardiac arrest [usually in patients with concurrent, severe proarrhythmic conditions]), vasculitis, vision loss (transient).